Clinical Trials

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06325748 2026-02-12

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

MyeloidOther hematologic neoplasmPlasma cell

21 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Multiple Myeloma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT06253663 2025-12-16

JKART-1

Phase 2 Active not recruiting

25 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT02379520 2025-11-28

HESTIA

Phase 2 Active not recruiting

32 enrolled

Neoplasms, Recurrence

NCT04245839 2025-11-05

TRANSCEND FL

276 enrolled 2 FDA

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT03263936 2025-10-16

Epigenetic Reprogramming in Relapse/Refractory AML

Phase 1 Completed

37 enrolled 11 charts

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT04678336 2025-10-15

CD123 Redirected T Cells for AML in Pediatric Subjects

Phase 1 Terminated

12 enrolled

Phase 1/2 Active not recruiting

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT02625480 2025-09-29

ZUMA-4

95 enrolled

Phase 1/2 Active not recruiting

Recurrence, Lymphoma, B-Cell

NCT04697940 2025-09-19

Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL

33 enrolled

Phase 1 Enrolling by invitation

Recurrence, Lymphoma, B-Cell

NCT06347068 2025-09-16

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

Phase 1 Recruiting

42 enrolled

Breast

Breast Neoplasms, Recurrence, Triple Negative Breast Neoplasms

NCT06305299 2025-09-15

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

Phase 1 Recruiting

27 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Recurrence

NCT07168486 2025-09-11

CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas

15 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Lymphoma, Follicular, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06986434 2025-09-03

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms

20 enrolled

Plasma cell

Recurrence, Neoplasms, Plasma Cell

NCT05883449 2025-08-20

LuminICE-203

Phase 2 Terminated

25 enrolled 21 charts

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Peripheral

NCT04608487 2025-07-30

Axi-cel in CNS Lymphoma

18 enrolled

Lymphoma, Recurrence

NCT06838832 2025-07-30

Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL

Phase 1/2 Recruiting

30 enrolled

Recurrence

NCT05963217 2025-07-02

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Phase 1 Recruiting

19 enrolled

Immune System Diseases, Lymphoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Experimental, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03766126 2025-06-26

Lentivirally Redirected CD123 Autologous T Cells in AML

22 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT06802315 2025-06-25

BMT-13

Phase 2 Recruiting

38 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Acute

NCT05972720 2025-05-15

FIRCE-1

Phase 2 Terminated

101 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT01822652 2025-02-24

GRAIN

11 enrolled

CNS

Neuroblastoma, Recurrence

NCT06834529 2025-02-19

CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma

Phase 1/2 Recruiting

20 enrolled

Phase NA Not yet recruiting

Lymphoma, Recurrence, Leukemia, B-Cell, Lymphoma, B-Cell

NCT03658785 2024-08-13

Immunotherapy for the Treatment of Advanced Solid Tumor

Phase 1/2 Recruiting

40 enrolled

Neoplasm Metastasis, Recurrence

NCT06385808 2024-04-26

Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML

37 enrolled

Phase 2 Not yet recruiting

Recurrence, Leukemia, Myeloid, Acute

NCT06367114 2024-04-19

Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)

50 enrolled

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03056339 2024-03-25

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

Phase 1/2 Completed

49 enrolled 12 charts

Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03624036 2023-11-18

ZUMA-8

Phase 1 Terminated

16 enrolled 17 charts

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04825496 2023-09-21

Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 1 Unknown

18 enrolled

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04613557 2023-08-31

IMMUNICY-1

18 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT03215810 2023-07-24

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

Phase 1 Completed

20 enrolled 10 charts

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Recurrence, Carcinoma, Adenosquamous

NCT02431988 2023-04-28

COBALT

Phase 1 Completed

10 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05797948 2023-04-04

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase NA Unknown

20 enrolled

Recurrence, Lymphoma, B-Cell

NCT05727683 2023-02-14

CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia

Phase 1 Unknown

33 enrolled

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04706936 2023-02-06

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Phase 1 Unknown

25 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT04030195 2023-01-31

Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL

Phase 1/2 Completed

18 enrolled 13 charts